1. Scrip
  2. >>Business

Novo Nordisk: Semaglutide Heralds Commercial Dawn Of Obesity Market

 
• By Sten Stovall

The Danish group expects its experimental GLP-1 semaglutide to prove so effective and safe in fighting obesity that it will spur commercial viability for medical treatment of the condition.

Overweight
Semaglutide Will Lead Commercial Dawning Of Global Obesity Market, Novo Nordisk Believes • Source: Shutterstock

A rising tide lifts all boats.

Denmark-based Novo Nordisk AS expects to benefit commercially - amid the surging obesity pandemic worldwide - from the eventual launch of its new GLP-1 agonist semaglutide,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business